Out-of-pocket costs for commercially insured patients with localized prostate cancer
Christopher J.D. Wallis(University Health Network), Daniel A. Barocas(Vanderbilt University Medical Center), Aaron A. Laviana(Vanderbilt University Medical Center), Daniel Joyce(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Amy N. Luckenbaugh(Vanderbilt University Medical Center), Zachary Klaassen(Augusta University), Stacie B. Dusetzina(University of North Carolina at Chapel Hill)
Urologic Oncology Seminars and Original Investigations
September 30, 2021
Cited by 10
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592